Growth opportunity Small team with a global footprint in autologous fat grafting suggests a partnership-driven sales approach, focusing on expanding adoption of Puregraft technology through clinical education campaigns, distributor partnerships, and strategic OEM collaborations to reach more surgeons and hospitals.

Regulatory leverage FDA clearance and CE marking indicate a validated device suitable for cross-border sales; target expansion through regulatory-ready market entries, training programs, and aftercare support to capitalize on international demand and reduce adoption barriers.

Clinical momentum Ongoing and past campaigns around breast reconstruction imply strong interest in reconstructive applications; sales reps should align with surgeons’ patient outcomes data, offer pilot programs, and build value propositions around regenerative benefits and repeat usage.

Financial signals Sub-$1M revenue band signals high-growth potential and room for scalable sales; focus on multi-channel marketing, tiered pricing discussions, bundled offerings with consumables, and regional expanded access to accelerate revenue growth.

Partnership pathways History of distribution agreements and collaborations with established players suggests pursuing new distribution, co-marketing, and training arrangements with compatible medical device firms to broaden market reach and speed up adoption.